In a remarkable breakthrough for feline health, a recent study has unveiled the astounding success of NexGard® Combo, a topical solution, in combating Feline pulmonary capillariosis—a lungworm infection caused by Eucoleus aerophilus, known for its widespread distribution and severe clinical effects on cats. This parasitic infection, challenging to manage due to its significant impact on a cat's respiratory health, may now be effectively treated with an innovative approach.

The study meticulously divided cats into two groups: the first received two doses of NexGard® Combo 28 days apart, while the second served as a control before receiving the same treatment. The efficacy of this regimen was evaluated through detailed coproscopy, clinical examinations, and chest radiographs over six weeks.

The results were nothing short of astonishing. NexGard® Combo demonstrated a staggering 99.5% to 100% efficacy in reducing egg shedding in feces after just two treatments. Moreover, the treated cats showed significant improvements in clinical symptoms, including reductions in oculo-nasal discharge, auscultation noises, and cough, highlighting not only the treatment's effectiveness in eradicating the lungworm but also its impact on enhancing the cats' overall respiratory health.

This study marks a significant milestone in the fight against feline pulmonary capillariosis, offering hope to cat owners and veterinarians alike. NexGard® Combo's success story opens up new avenues for the prevention and treatment of this challenging infection, promising a healthier, happier future for our feline friends.

Read full article here: https://pubmed.ncbi.nlm.nih.gov/38315065/